Drug Trial Radar · NCT06623526
Clinical Trial to Evaluate the PK Interactions of YHR2402 Monotherapy and YHR2402 and YHR2403 Co-Administration in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Nov 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Oct 4, 2024
Primary completion
Nov 6, 2024
Study completion Nov 11, 2024
Sponsor
- Lead sponsor
- Yuhan CorporationIndustry
- Sponsor type
- Industry
- First posted
- Oct 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
An open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetic interactions and safety after co-administration of YHR2402 and YHR2403 compared to the administration of YHR2402 independently in healthy subjects
Conditions
- Healthy Volunteers
Interventions
YHR2402Drug
Test Drug: YHR2402
YHR2402+YHR2403Drug
Test Drug: YHR2402+YHR2403
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma drug concentration-time curve [AUCt]Time frame: 0-96 hours
- Maximum plasma concentration [Cmax]Time frame: 0-96 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jeonbuk National University Hospital
Jeonju, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.